The blue pill (sildenafil) and its descendants: an overview

Tomasz Krzanowski; Lila Dabkowska; Monika Wujec; Ewa Kedzierska

doi:10.1515/cipms-2017-0023

.blurhash-client-img { display: none !important; }

The blue pill (sildenafil) and its descendants: an overview

Current Issues in Pharmacy and Medical Sciences

Volume 30 (2017): Issue 3 (December 2017)

By: Tomasz Krzanowski, Lila Dabkowska, Monika Wujec and Ewa Kedzierska

Open Access

|Dec 2017

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA.1993;270(1):83-90.10.1001/jama.1993.03510010089036
Open DOI Search in Google Scholar Back to article
2. Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731-40. doi: 10.1007/s11255-017-1644-5.
Open DOI Search in Google Scholar Back to article
3. Izdebski Z. Seksualność Polakow na początku XXI wieku. Studium badawcze. Krakow: Wyd. UJ; 2012:287-92.
Search in Google Scholar Back to article
4. Szurgociński A. Zaburzenia erekcji w Polsce. Grodzisk Mazowiecki: Vedi Clinic;2016.
Search in Google Scholar Back to article
5. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther. 2001;296(2):225-34.
Search in Google Scholar Back to article
6. Rabijewski M. Zaburzenia erekcji - etiologia i leczenie. Przegl. Urol. 2006;4(38):46.
Search in Google Scholar Back to article
7. Izdebski Z. Obawy i trudności w życiu seksualnym. Rocz Lubus. 2006;32(2):13-8.
Search in Google Scholar Back to article
8. Dęmbe K, Jasik M, Stawicki S, Karnafel W. Patogeneza i częstość zaburzeń erekcji u chorych na cukrzycę. Seksuol Pol. 2004;2 (2):51-54.
Search in Google Scholar Back to article
9. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-14. doi: 10.1016/j.eururo.2010.02.020.
Open DOI Search in Google Scholar Back to article
10. Ferguson JE, Carson CC. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. Arab J Urol. 2013;11(3):222-229. doi: 10.1016/j. aju.2013.07.009.
Open DOI Search in Google Scholar Back to article
11. Woroń J, Kostka-Trąbka E. Zaburzenia erekcji jako wynik niepożądanego działania lekow. Seksuol Pol. 2005;3:18-22.
Search in Google Scholar Back to article
12. Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827.
Search in Google Scholar Back to article
13. Rosen RC. Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am. 2001;28(2):269-78.10.1016/S0094-0143(05)70137-3
Open DOI Search in Google Scholar Back to article
14. Reisman Y, Hind A, Varaneckas A, Motil I. Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA)-A Second Generation Technology. Int J Impot Res. 2015;27(3):108-12. doi: 10.1038/ijir.2014.41.
Open DOI Search in Google Scholar Back to article
15. Snyder PJ, Ellenberg SS, Farrar JT. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-24. doi: 10.1056/NEJMc 1603665.
Open DOI Search in Google Scholar Back to article
16. Anaissie J, Hellstrom WJ. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123.
Search in Google Scholar Back to article
17. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int. 2001;67(4):257-63.10.1159/00005100111741126
Open DOI Search in Google Scholar Open in PubMed Back to article
18. Rabijewski M, Papierska L. Pathogenesis and treatment of erectile dysfunction. Ger Pol. 2007;1:203-8.
Search in Google Scholar Back to article
19. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404.10.1056/NEJM1998051433820019580646
Open DOI Search in Google Scholar Open in PubMed Back to article
20. McCullough AR. Four-year review of sildenafil citrate. Reviews in Urology. 2002;4,Suppl 3:26.
Search in Google Scholar Back to article
21. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman Metal. British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5:1841-65.10.1111/j.1743-6109.2008.00773.x18298470
Open DOI Search in Google Scholar Open in PubMed Back to article
22. Lew-Starowicz Z. Inhibitory fosfodiesterazy typu 5 - podobieństwa i rożnice. Seksuol Pol. 2003;(2):79-82.
Search in Google Scholar Back to article
23. Liu Y. The tale of Viagra patents: comparative studies of the global challenges in China and other countries. 2013;18:523-33.
Search in Google Scholar Back to article
24. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. P T. 2013;38(7):407-19.
Search in Google Scholar Back to article
25. Jiann BP. Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. Urol Sci. 2016;27 (2):66-70.10.1016/j.urols.2016.04.003
Open DOI Search in Google Scholar Back to article
26. Cho MC, Paick JS. Udenafil for the treatment of erectile dysfunction. Ther Clin Risk Manag. 2014;10:341-54. doi: 10.2147/TCRM.S39727.
Open DOI Search in Google Scholar Back to article
27. Zhao C, Kim SW, Yang DJ, Kim JJ, Park NC, Lee SW et al. Efficacy and Safety of Once-Daily Dosing of Udenafil in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double- Blind, Placebo-Controlled Trial. Eur Urol. 2011;60(2):380-7. doi: 10.1016/j.eururo.2011.03.025.
Open DOI Search in Google Scholar Back to article
28. Kim TE, Kim BH, Kim JR, Lim KS, Hong JH, Kim KP et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43-6. doi: 10.1111/j.1365-2125.2009.03404.x.
Open DOI Search in Google Scholar Back to article
29. http://www.mims.com/malaysia/drug/info/zydena/
Search in Google Scholar Back to article
30. LevitraR (vardenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2009. Last update: 06/04/2017
Search in Google Scholar Back to article
31. CialisR (tadalafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2007. Last update: 15/06/2016.
Search in Google Scholar Back to article
32. ViagraR (sildenafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2008. Last update: 12/07/2016
Search in Google Scholar Back to article
33. SpedraR (avanafil) Scientific Discussion & Summary of Product Characteristics. European Medicine Agency: London, GB. 2013. Last update: 10/03/2015.
Search in Google Scholar Back to article
34. Stendra (avanafil), prescribing information. Mountainview, Calif.: Vivus, Inc.; April 2012.
Search in Google Scholar Back to article
35. Staxyn (vardenafil ODT), prescribing information. Wayne, NJ.; Bayer Healthcare/GlaxoSmithKline; revised April 2011.
Search in Google Scholar Back to article
36. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000;28(4):392-7.
Search in Google Scholar Back to article
37. Jetter A, Kinzig‐Schippers M, Walchner‐Bonjean M, Hering U, Bulitta J, Schreiner P et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 2002;71(1):21-9.10.1067/mcp.2002.12123611823754
Open DOI Search in Google Scholar Open in PubMed Back to article
38. Young JM. Vardenafil. Expert. Opin. Investig. Drugs 2002;11:1487-96.
Search in Google Scholar Back to article
39. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur. J. Med. Res. 2002;7:435-46.
Search in Google Scholar Back to article
40. Kloner RA, Mullin SH, Shook T et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J. Urol. 2003;170 (2):S46-50.10.1097/01.ju.0000075055.34506.5912853773
Open DOI Search in Google Scholar Open in PubMed Back to article
41. Swearingen D, Nehra A, Morelos S, Peterson CA. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;26:212248. doi: 10.7573/dic.212248.
Open DOI Search in Google Scholar Back to article
42. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P et al. Safety of sildenafi l citrate: review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-55.10.1111/j.1742-1241.2009.02254.x281044819900167
Open DOI Search in Google Scholar Open in PubMed Back to article
43. Kuczerowski R. Nowe możliwości leczenia zaburzeń erekcji u mężczyzn z cukrzycą typu 2. Diabetologia Kliniczna 2015;4 (4):158-62. doi: 10.5603/DK.2015.0017.
Open DOI Search in Google Scholar Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.1515/cipms-2017-0023 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 129 - 133

Submitted on: Sep 9, 2017

Accepted on: Sep 25, 2017

Published online: Dec 29, 2017

Published in print: Sep 26, 2017

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Keywords:

erectile dysfunction,

phosphodiesterase type 5 inhibitor,

PDE-5-inhibitor

Related subjects:

Medicine,

Clinical medicine,

Pharmacology, toxicology

© 2017 Tomasz Krzanowski, Lila Dabkowska, Monika Wujec, Ewa Kedzierska, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 30 (2017): Issue 3 (December 2017)